# OnCo record rockstar (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rockstar/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rockstar", "NCT03640481" ;
  schema:name "ROCKstar"@en ;
  schema:alternateName "KD025-213"@en, "DRI17633"@en, "The ROCKstar Study"@en ;
  schema:description "ROCKstar showed that belumosudil, a daily pill, improved chronic graft-versus-host disease in about three in four people whose disease had not settled after at least two earlier treatments, which led to its US approval in 2021."@en ;
  schema:url <https://onco.cc/trials/rockstar/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03640481>, <https://doi.org/10.1182/blood.2021012021>, <https://doi.org/10.1158/1078-0432.CCR-21-4176>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=102e4ef4-7f84-4e34-8df1-479c24d1575d> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/belumosudil/> ;
  onco:companies <https://onco.cc/companies/sanofi/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/allogeneic-transplant/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rockstar-blood-2021/> .